Feasibility and clinical significance of real-time quantitative RT-PCR assay of PML-RARα fusion transcript in patients with acute promyelocytic leukemia

Hematology Journal

Volumn 2, Issue 5, 2001, Pages 330-340

  Gu, B W ^a   Hu, J ^a   Xu, L ^a   Yan, H ^a   Jin, W R ^a   Zhu, Y M ^a   Zhao, W L ^a   Niu, C ^a   Cao, Q ^a   Su, X Y ^a   Gu, J ^a   Ying, H Y ^a   Chen, Y ^a   Xiong, S M ^a   Shen, Z X ^a   Chen, Z ^a   Chen, S J ^a  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

Author keywords

Acute promyelocytic leukemia (APL); PML RAR ; Real time reverse transcription polymerase chain reaction (real time RT PCR); Taqman

Indexed keywords

ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; RETINOIC ACID; RETINOIC ACID RECEPTOR;

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CHINA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; FEASIBILITY STUDY; FEMALE; FUSION GENE; GENE EXPRESSION; HOSPITAL PATIENT; HUMAN; LEUKEMIA REMISSION; MALE; MEDICAL ASSESSMENT; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; BONE MARROW; CHILD; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEASIBILITY STUDIES; FEMALE; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM, RESIDUAL; ONCOGENE PROTEINS, FUSION; PROGNOSIS; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY;

EID: 0034769846     PISSN: 14664860     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.thj.6200128     Document Type: Article

References (35)

1. All-transretinoic acid in acute promyelocytic leukemia
2. Deconstructing a disease: RARα, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia
3. Evidence for a 15;17 translocation in every patient with acute promyelocytic leukemia
4. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML
5. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus
6. Molecular rearrangements of the MYL gene in acute promyelocytic leukemia (APL, M3) define a breakpoint cluster region as well as some molecular variants
7. Use of all-trans-retinoic acid in the treatment of acute promyelocytic leukemia
8. Acute promyelocytic leukemia: A curable disease
9. Genomic variability and alternative splicing generate multiple PML/RAR alpha transcripts that encode aberrant PML proteins and PML/RAR alpha isoforms in acute promyelocytic leukaemia
10. Occurrence of distinct PML-RARα fusion gene isoforms in patients with acute promyelocytic leukemia detected by reverse transcriptase/polymerase chain reaction
11. Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor alpha clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia
12. Acute promyelocytic leukemia: Clinical relevance of two major PML-RAR alpha isoforms and detection of minimal residual disease by retrotranscriptase/polymerase chain reaction to predict relapse
13. Molecular monitoring of the myl/retinoic acid receptor-alpha fusion gene in acute promyelocytic leukemia by polymerase chain reaction
14. Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukaemia
15. Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes
16. Detection of BCR-ABL transcripts in chronic myeloid leukemia (CML) using a 'real time' quantitative RT-PCR assay
17. Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia patients using real-time quantitative RT-PCR
18. Detection of minimal residual disease in patients with AML1/ETO-associated acute myeloid leukemia using a novel quantitative reverse transcription polymerase chain reaction assay
19. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group
20. Long-term survival and prognostic study in acute promyelocytic leukemia treated with all-trans-retinoic acid, chemotherapy, and As2O3: An experience of 120 patients at a single institution
21. Detection of specific polymerase chain reaction product by utilizing the 5′-3′ exonuclease activity of Thermus aquaticus DNA polymerase
22. A novel method for real time quantitative RT-PCR
23. Real time quantitative PCR
24. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
25. Differentiation and apoptosis induction therapy in acute promyelocytic leukemia
26. Disappearance of PML/RAR alpha acute promyelocytic leukemia-associated transcript during consolidation chemotherapy
27. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Ematologia ed Oncologia Pediatrica Cooperative Groups
28. Molecular analysis of PML-RAR alpha fusion mRNA detected by reverse transcription-polymerase chain reaction assay in long-term disease-free acute promyelocytic leukaemia patients
29. Quantitation of minimal residual disease in acute promyelocytic leukemia patients with t(15;17) translocation using real-time RT-PCR
30. Monitoring of minimal residual disease by quantitative reverse transcriptase-polymerase chain reaction for AML1-MTG8 transcripts in AML-M2 with t(8;21)
31. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: Remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients
32. Absence of detectable PML-RAR alpha fusion transcripts in long-term remission patients after BMT for acute promyelocytic leukemia
33. AIDA (all-trans retinoic acid+idarubicin) in newly diagnosed acute promyelocytic leukemia: A Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study
34. Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RAR alpha fusion gene in patients with acute promyelocytic leukemia enrolled in the trial. GIMEMA-AIEOP Multicenter "AIDA" Trial
35. PML-RAR alpha PCR positivity in the bone marrow of patients with APL precedes haematological relapse by 2-3 months